Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:50 2024-04-30 am EDT			5-day change	1st Jan Change
1,956 ^DKK	-0.69%		-2.56%	-9.21%

05:18pm	Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	MT
05:55am	Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	MT

Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024

April 16, 2024 at 06:24 am EDT

Genmab A/S announced DARZALEX sales results for the first quarter of 2024. For the quarter, the company reported net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million. Net trade sales were USD 1,464 million in the U.S. and USD 1,228 million in the rest of the world.

Latest news about Genmab A/S

Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer	11:18am	MT
Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment	11:55pm	MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer	06:40pm	CI
Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug	Apr. 29	DJ
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	Apr. 16	MT
Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024	Apr. 16	CI
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Health Care Flat on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	Apr. 03	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 AM ET	Apr. 03	DJ
Global markets live: Swiss Re, Intel, Walt Disney, Paramount, Microsoft...	Apr. 03
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	Apr. 03	DJ
Correction to Genmab Article	Apr. 03	DJ
Genmab: acquisition of ProfoundBio greeted without emotion	Apr. 03	CF
News Highlights : Top Company News of the Day - Wednesday at 7 AM ET	Apr. 03	DJ
Genmab A/S Re-Affirms Revenue Guidance for the Year 2024	Apr. 03	CI
Transcript : Genmab A/S, ProfoundBio - M&A Call	Apr. 03
European Midday Briefing : Stocks Continue to Struggle Despite Cooling Inflation	Apr. 03	DJ
News Highlights : Top Company News of the Day - Wednesday at 5 AM ET	Apr. 03	DJ
Genmab Strengthens Oncology Portfolio With $1.8 Billion Acquisition of ProfoundBio	Apr. 03	DJ
Genmab Looks to Expand Clinical Pipeline with $1.8 Billion Purchase of Cancer-focused ProfoundBio	Apr. 03	MT
Denmark's Genmab to acquire ProfoundBio for $1.8 billion	Apr. 03	RE
Genmab to Acquire ProfoundBio for $1.8 Billion	Apr. 03	MT
Genmab to Purchase US-based ProfoundBio for $1.8 Billion	Apr. 03	MT
Genmab A/S entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.	Apr. 02	CI
Genmab A/S commences an Equity Buyback Plan under the authorization approved on March 13, 2024.	Mar. 25	CI

Chart Genmab A/S

Duration

Period

More charts

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GENMAB : Genmab is available at a bargain price

March 04, 2024 at 06:10 am EST

More Strategies

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,970 DKK

Average target price

2,463 DKK

Spread / Average Target

+25.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENMAB A/S	-9.21%	18.31B
VERTEX PHARMACEUTICALS INCORPORATED	-3.13%	102B
REGENERON PHARMACEUTICALS, INC.	+1.90%	96.29B
ARGENX SE	+2.27%	22.18B
BIONTECH SE	-15.25%	21.2B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-15.11%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.43%	13.97B
SAREPTA THERAPEUTICS, INC.	+31.96%	12.17B
VIKING THERAPEUTICS, INC.	+307.58%	8.32B

Bio Therapeutic Drugs